News Column

Regulus Reports Second Quarter 2014 Financial Results and Recent Highlights

August 20, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, reported financial results and highlights for the quarter ended June 30, 2014 and provided a summary of recent corporate highlights (see also Regulus Therapeutics Inc.).

"The first half of 2014 has been a period of steady progress for us as represented by the growth of our clinical and preclinical portfolios under our 'Clinical Map Initiative', the expansion of our strategic relationships and our consistently strong financial position, all which support our leadership position in the microRNA therapeutics field," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "Recently, we were pleased to report additional progress on the business front with the expansion of our relationship with Biogen Idec to identify microRNA biomarkers for multiple sclerosis. The Regulus microMarkers™ division continues to mature and we hope to leverage our innovative technology platform to further advance our microRNA therapeutic pipeline, our collaborations and partners' programs in a meaningful way."

Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus, added, "We are very pleased with our recent scientific progress and hope to extend our good track record into the second half of 2014. We have several significant catalysts on the horizon - by the end of the year, we have the opportunity to report our first human proof of concept results with a microRNA therapeutic, strengthen our focus on orphan diseases by advancing RG-012 toward the clinic, and expand our overall microRNA therapeutics pipeline with the nomination of a third candidate for clinical development."

Keywords for this news article include: Regulus Therapeutics Inc..

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters